provid
convalescentphas
serum
sampl
patient
confirm
sar
peptidebas
enzymelink
immunosorb
assay
elisa
use
retrospect
serosurveil
sever
acut
respiratori
syndrom
sar
help
identifi
undetect
chain
diseas
transmiss
assay
develop
epitop
map
use
synthet
peptid
spike
membran
nucleocapsid
protein
sequenc
sarsassoci
coronaviru
new
peptid
elisa
consist
detect
seroconvers
week
onset
fever
seroposit
remain
day
specif
normal
blood
donor
sampl
serum
sampl
associ
infect
pathogen
interfer
panel
peptidebas
test
advantag
safeti
standard
autom
previou
immunoassay
sar
assay
use
retrospect
survey
healthi
healthcar
worker
taiwan
treat
sar
patient
asymptomat
seroconvers
detect
two
hospit
nosocomi
diseas
r
etrospect
surveil
infect
import
mean
screen
interrupt
undetect
chain
diseas
transmiss
surveil
may
key
track
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
mild
asymptomat
case
sarscov
infect
meet
world
health
organ
case
definit
identifi
immunoassay
sarscovlik
virus
isol
wild
mammal
sarscov
may
persist
summer
previous
affect
area
difficulttorecogn
reservoir
reemerg
sar
citi
guangzhou
guangdong
provinc
china
decemb
januari
evid
unknown
reservoir
exist
signal
need
continu
surveil
laboratori
test
current
laboratori
method
identifi
sar
ideal
tool
use
retrospect
mass
screen
revers
transcriptionpolymeras
chain
reaction
rtpcr
detect
viral
rna
sensit
method
earli
identif
sar
howev
viral
load
rapidli
declin
begin
day
diseas
onset
moreov
rtpcr
requir
sophist
equip
high
laboratori
qualityassur
standard
identifi
seroconvers
sarscov
immunoassay
also
definit
criterion
laboratori
determin
sar
seroconvers
prefer
standard
retrospect
detect
sarscov
infect
sar
immunoassay
includ
enzymelink
immunosorb
assay
elisa
western
blot
antigen
whole
viru
variou
recombin
protein
cumbersom
immunofluoresc
assay
ifa
use
whole
viru
fix
glass
method
determin
neutral
antibodi
immunoglobulin
ig
g
sarscov
detect
immunoassay
begin
rise
sharpli
day
onset
symptom
virtual
sar
patient
show
virusspecif
antibodi
week
antisarscov
igg
persist
day
although
immunoassay
provid
definit
laboratori
find
recombin
test
requir
biosafeti
level
contain
viru
timeconsum
perform
wellstandard
unknown
specif
would
difficult
adapt
largescal
manufactur
improv
laboratori
method
largescal
serolog
surveil
sar
particularli
presenc
respiratori
ill
standard
diagnost
assay
key
prioriti
control
sar
report
standard
rapid
peptidebas
sar
elisa
character
sensit
specif
begin
april
delay
recogn
sar
case
implement
isol
procedur
led
sever
nosocomi
cluster
sarscov
transmiss
healthcar
facil
taiwan
result
retrospect
serolog
survey
peptid
elisa
healthcar
worker
facil
affect
nosocomi
outbreak
present
work
exampl
develop
elisa
sar
synthet
peptid
antigen
solidphas
immunosorb
overlap
peptid
deduc
sarscov
genom
sequenc
synthes
candid
antigen
spike
membran
nucleocapsid
n
protein
candid
immunodomin
n
peptid
select
refin
basi
serolog
reactiv
panel
serum
sampl
patient
clinic
diagnos
sar
nation
taiwan
univers
hospit
taipei
xiaotangshan
sar
emerg
hospit
beij
epitop
map
serolog
valid
describ
develop
peptidebas
elisa
test
hiv
hepat
c
viru
footandmouth
diseas
viru
peptidebas
sar
elisa
well
microtit
plate
coat
mixtur
n
proteinderiv
peptid
serolog
reactiv
determin
standard
elisa
procedur
previous
describ
except
detector
horseradish
peroxidaseconjug
goat
antihuman
igg
chromaphor
tmb
brief
serum
sampl
includ
two
normal
human
sampl
provid
nonreact
control
dilut
phosphatebuff
salin
carrier
protein
preserv
dilut
serum
sampl
react
peptideco
microtit
well
l
h
plate
wash
time
react
antibodi
conjug
wash
time
react
tmb
reactiv
determin
assay
result
obtain
within
h
result
score
basi
signalcutoff
sc
ratio
cutoff
absorb
determin
mean
two
control
plu
standard
deviat
sd
distribut
normal
human
sampl
figur
seroconvers
panel
collect
serial
serum
sampl
sar
patient
nation
taiwan
univers
hospit
cours
treatment
panel
test
posit
seroconvers
ifa
use
evalu
analyt
sensit
panel
serum
sampl
convalesc
sar
patient
provid
center
diseas
control
depart
health
taiwan
evalu
diagnost
sensit
serum
specimen
confirm
sarscov
infect
clinic
world
health
organ
diagnost
criteria
serolog
whole
virusbas
elisa
ifa
specimen
also
confirm
rtpcr
sampl
drawn
appropri
time
serolog
reactiv
week
onset
symptom
panel
plasma
sampl
collect
random
blood
donor
florida
obtain
gulf
coast
region
blood
center
houston
tx
specif
evalu
addit
specif
studi
conduct
serum
serolog
reactiv
bloodborn
pathogen
hepat
c
viru
htlv
syphili
obtain
unit
biomed
inc
variou
us
sourc
interfer
panel
suppli
boston
biomedica
inc
boston
serum
sampl
interfer
substanc
commonli
found
process
clinic
sampl
edta
acid
citrat
dextros
citrat
phosphat
dextros
adenin
serum
suppli
nation
taiwan
univers
hospit
patient
associ
typic
atyp
respiratori
pathogen
sarscov
influenza
rubella
cytomegaloviru
epsteinbarr
viru
mycoplasma
pneumonia
serum
sampl
collect
healthi
healthcar
worker
interview
confirm
lack
sign
symptom
sar
includ
fever
respiratori
symptom
diarrhea
peptidebas
elisa
evalu
sensit
seroconvers
eight
seroconvers
panel
obtain
nation
taiwan
univers
hospit
figur
tabl
patient
seroconvers
detect
day
absorb
remain
day
patient
blood
drawn
day
sampl
collect
day
day
seroconvers
appar
day
onset
fever
day
remain
five
six
seroconvers
panel
acut
convalesc
phase
seroposit
observ
day
day
patient
serum
collect
day
figur
peptidebas
elisa
show
analyt
sensit
earliest
time
detect
week
durat
detect
beyond
day
seroreact
patient
also
evalu
standard
ifa
method
comparison
seroconvers
detect
six
patient
ifa
method
within
day
peptid
elisa
data
shown
diagnost
sensit
peptid
elisa
panel
convalescentphas
serum
sampl
sar
patient
provid
refer
panel
center
diseas
control
depart
health
taiwan
sera
confirm
sar
diagnost
serolog
criteria
display
mean
sc
ratio
figur
specif
peptidebas
sar
elisa
test
plasma
obtain
random
florida
blood
donor
gulf
coast
region
blood
center
houston
tx
normal
plasma
sampl
presum
zero
seropreval
rate
gave
mean
sd
subsequ
cutoff
valu
peptidebas
assay
set
mean
duplic
nonreact
control
plu
base
sd
mean
normal
plasma
sampl
distribut
sc
ratio
blood
bank
sampl
plot
figur
mean
sc
ratio
none
show
posit
reactiv
specif
normal
sampl
tabl
peptid
elisa
evalu
specif
collect
serum
sampl
patient
seroposit
bloodborn
pathogen
hiv
hepat
c
viru
htlv
syphili
variou
us
sourc
normal
serum
sampl
spike
interfer
substanc
heparin
edta
acd
boston
biomedica
sampl
seroreact
pathogen
test
neg
peptidebas
sar
elisa
interfer
panel
tabl
peptid
elisa
evalu
specif
serum
sampl
drawn
patient
associ
typic
atyp
respiratori
pathogen
sarscov
nation
taiwan
univers
hospit
includ
sampl
patient
natur
infect
influenza
two
sequenti
bleed
per
influenza
patient
patient
rubella
bacteri
agent
atyp
pneumonia
preand
postvaccin
blood
sampl
patient
given
influenza
vaccin
sampl
test
duplic
sitespecif
antigen
peptid
sarscov
elisa
free
crossreact
respiratori
pathogen
tabl
prospect
studi
perform
determin
asymptomat
infect
among
primari
healthcar
worker
hospit
treat
sar
patient
collect
serum
sampl
healthcar
worker
without
symptom
direct
contact
sar
patient
agre
test
antibodi
sarscov
ho
ping
yang
ming
en
chu
kong
hsin
tai
hospit
approxim
week
outbreak
recogn
ho
ping
yang
ming
hospit
admit
sar
patient
recognit
sar
healthcar
worker
implement
control
measur
subsequ
facil
experienc
transmiss
healthcar
worker
en
chu
kong
hsin
tai
facil
admit
patient
control
measur
implement
neither
hospit
record
transmiss
sar
healthcar
worker
elisa
detect
three
case
sampl
ho
ping
one
case
blood
sampl
nurs
aid
yang
ming
four
posit
sampl
indic
asymptomat
infect
confirm
seroposit
ifa
none
serum
sampl
two
hospit
without
nosocomi
infect
display
seroconvers
conveni
elisa
detect
igg
sarscov
base
sitespecif
synthet
antigen
taken
n
protein
viru
high
specif
crossreact
detect
sampl
associ
common
noncoronaviru
respiratori
pathogen
addit
lack
detect
reactiv
among
us
blood
donor
support
specif
assay
distinguish
sarscov
infect
infect
human
coronavirus
presenc
anticoronaviru
antibodi
among
us
popul
size
strongli
anticip
incid
high
respiratori
infect
observ
even
among
healthi
young
adult
new
peptidebas
elisa
equival
sensit
immunoassay
sar
detect
day
synthet
antigen
provid
advantag
high
standard
freedom
biohazard
eas
scaleup
product
moreov
test
elisa
format
readili
autom
largescal
screen
highli
specif
peptidebas
sar
antibodi
test
conveni
mean
carri
widespread
retrospect
surveil
propos
china
trace
hotspot
person
carri
antibodi
sarscov
track
origin
diseas
preliminari
survey
peptid
elisa
detect
asymptomat
cluster
seroconvers
among
expos
healthcar
worker
two
taiwan
hospit
also
nosocomi
diseas
contrast
seroconvers
found
among
expos
healthcar
worker
two
hospit
appar
diseas
transmiss
healthcar
worker
find
asymptomat
seroposit
person
indic
test
use
larger
retrospect
surveil
studi
need
fulli
defin
epidemiolog
spectrum
diseas
protocol
inform
consent
document
approv
ethic
committe
medic
research
biomed
scienc
academia
sinica
particip
voluntari
document
written
inform
consent
dr
hsueh
associ
professor
depart
laboratori
medicin
intern
medicin
nation
taiwan
univers
hospit
nation
taiwan
univers
colleg
medicin
research
interest
includ
mechan
microbi
resist
molecular
epidemiolog
emerg
pathogen
activ
involv
nation
research
program
antimicrobi
drug
resist
member
sar
research
group
nation
taiwan
univers
colleg
medicin
nation
taiwan
univers
hospit
